Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study

References

• AllisonACEuguiEMImmunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetilImmunol Rev19931365287907572
   PubMed Web of Science ®Google Scholar
• WuJCMycophenolate mofetil: molecular mechanisms of actionPerspectives in Drug Discovery and Design19942185204
   Google Scholar
• BullinghamRENichollsAHaleMPharmacokinetics of mycophenolate mofetil (RS61443): a short reviewTransplant Proc1996289259298623466
   PubMed Web of Science ®Google Scholar
• ZizzoGDe Santis M, Ferraccioli GF. Mycophenolic acid in rheumatology: mechanisms of action and severe adverse eventsReumatismo2010629110020657885
   PubMedGoogle Scholar
• LeeWAGuLMiksztalARChuNLeungKNelsonPHBioavailability improvement of mycophenolic acid through amino ester derivatizationPharm Res199071611662308896
   PubMed Web of Science ®Google Scholar
• BehrendMAdverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and managementDrug Saf20012464566311522119
   PubMed Web of Science ®Google Scholar
• BuddeKGlanderPDiekmannFReview of the immunosuppressant enteric-coated mycophenolate sodiumExpert Opin Pharmacother200451333134515163278
   PubMed Web of Science ®Google Scholar
• SalvadoriMHolzerHde MattosAERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patientsAm J Transplant2004423123614974944
   PubMed Web of Science ®Google Scholar
• BuddeKCurtisJKnollGERL B302 Study GroupEnteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year studyAm J Transplant2004423724314974945
   PubMed Web of Science ®Google Scholar
• BuddeKBauerSHambachPPharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patientsAm J Transplant2007788889817391132
   PubMed Web of Science ®Google Scholar
• ChanLMulgaonkarSWalkerRArnsWAmbühlPSchiavelliRPatient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodiumTransplantation2006811290129716699457
   PubMed Web of Science ®Google Scholar
• BuddeKDürrMLiefeldtLNeumayerHHGlanderPEnteric-coated mycophenolate sodiumExpert Opin Drug Saf2010998199420795786
   PubMed Web of Science ®Google Scholar
• ManitpisitkulWLeeSCooperMMycophenolic acid agents: is enteric coating the answer?Transplant Research and Risk Management201134553
   Google Scholar
• BolinPJrGohhRKandaswamyRMycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter?Transplant Rev (Orlando)20112511712321530217
   PubMedGoogle Scholar
• CojocaruMCojocaruIMSilosiIVrabieCDGastrointestinal manifestations in systemic autoimmune diseasesMaedica (Buchar)20116455121977190
   PubMedGoogle Scholar
• MakACheakAATanJYSuHCHoRCLauCSMycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regressionRheumatology (Oxford)20094894495219494179
   PubMed Web of Science ®Google Scholar
• PisoniCNSanchezFJKarimYMycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patientsJ Rheumatol2005321047105215940766
   PubMed Web of Science ®Google Scholar
• DimenäsEGliseHHallerbäckBHernqvistHSvedlundJWiklundIWell-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcerScand J Gastroenterol199530104610528578162
   PubMed Web of Science ®Google Scholar
• DimenäsECarlssonGGliseHIsraelssonBWiklundIRelevance of norm values as part of the documentation of quality of life Instruments for use in upper gastrointestinal diseaseScand J Gastroenterol Suppl19962218139110389
   PubMedGoogle Scholar
• EypaschEWilliamsJIWood-DauphineeSGastrointestinal Quality of Life Index: development, validation and application of a new instrumentBr J Surg1995822162227749697
   PubMed Web of Science ®Google Scholar
• DupuyHJThe Psychological General Well-Being (PGWB) IndexWengerNKMattsonMEFurbergCDElinsonJAssessment of Quality of Life in Clinical Trials of Cardiovascular TherapiesNew York, NY, USALe Jacq Publishing1984
   Google Scholar
• JaeschkeRSingerJGuyattGHMeasurement of health status. Ascertaining the minimal clinically important differenceControl Clin Trials1989104074152691207
   PubMedGoogle Scholar
• KleinmanLKilburgAMachnickiGUsing GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLIQual Life Res2006151223123216972162
   PubMed Web of Science ®Google Scholar
• MachnickiGPefaurJGaiteLGastrointestinal (GI)-specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohortHealth Qual Life Outcomes200865318644133
   PubMed Web of Science ®Google Scholar
• KulichKRMalfertheinerPMadischAPsychometric validation of the German translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux diseaseHealth Qual Life Outcomes200316214613560
   PubMedGoogle Scholar
• CookCEClinimetrics corner: the minimal clinically important change score (MCID): a necessary pretenseJ Man Manip Ther200816E82E8319771185
   PubMedGoogle Scholar
• JollyMHow does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?J Rheumatol2005321706170816142864
   PubMed Web of Science ®Google Scholar
• YeattsRPQuality of life in patients with Graves ophthalmopathyTrans Am Ophthalmol Soc200510336841117057811
   PubMedGoogle Scholar
• BristerKYauCLSlakeyDEnteric coating of mycophenolate reduces dosage adjustmentsTransplant Proc2009411657165919545702
   PubMed Web of Science ®Google Scholar
• SommererCGlanderPArnsWSafety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patientsTransplantation20119177978521297553
   PubMed Web of Science ®Google Scholar
• BolinPTanrioverBZibariGBImprovement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patientsTransplantation2007841443145118091520
   PubMed Web of Science ®Google Scholar
• DarjiPVijayaraghavanRThiagarajanCMConversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disordersTransplant Proc2008402262226718790208
   PubMed Web of Science ®Google Scholar
• ToledoAHHendrixLBuchholzVImprovement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patientsClin Transplant20122615616321470310
   PubMed Web of Science ®Google Scholar
• ReinkePBuddeKHugoCReductions of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodiumTransplant Proc2011431641164621693250
   PubMed Web of Science ®Google Scholar
• LangoneAJChanLBolinPCooperMEnteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized studyTransplantation20119147047821245794
   PubMed Web of Science ®Google Scholar
• ShehataMBhandariSVenkat-RamanGEffect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantationTranspl Int20092282183019386081
   PubMed Web of Science ®Google Scholar
• FriedmanLMFurbergCDDeMetsDLAssessment of health-related quality of lifeFriedmanLMFurbergCDDeMetsDLFundamentals of Clinical TrialsNew York, NY, USASpringer2010
   Google Scholar
• RolandMBarbetCPaintaudGMycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic studyLupus20091844144719318398
   PubMed Web of Science ®Google Scholar
• De WinterBCMProefschriftVariability in the Pharmacokinetics of Mycophenolic Acid. Implications for Therapeutic Drug MonitoringRotterdam, The NetherlandsOptima Grafische Communicatie2010
   Google Scholar
• NeumannIHaidingerMJägerHPharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared to renal transplant recipientsJ Am Soc Nephrol20031472172712595508
   PubMed Web of Science ®Google Scholar
• Tedesco-SilvaHFelipeCRParkSIRandomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipientsClin Transplant201024E116E12320047618
   PubMed Web of Science ®Google Scholar
• TraitanonOAvihingsanonYKittikovitVEfficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective studyLupus20081774475118625653
   PubMed Web of Science ®Google Scholar
• ZeherMDoriaALanJEfficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritisLupus2011201484149321976398
   PubMed Web of Science ®Google Scholar
• KreuterATomiNSWeinerSMMycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapyBr J Dermatol20071561321132717408395
   PubMed Web of Science ®Google Scholar
• HaeckIMKnolMJTen BergeOEnteric-coated mycophenolate sodium versus cyclosporine A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trialJ Am Acad Dermatol2011641074108421458107
   PubMed Web of Science ®Google Scholar
• DeuterCMDoychevaDStuebigerNZierhutMMycophenolate sodium for immunosuppressive treatment in uveitisOcul Immunol Inflamm20091741541920001262
   PubMed Web of Science ®Google Scholar
• KarimMYPisoniCNKhamashtaMAUpdate on immunotherapy for systemic lupus erythematosus – what’s hot and what’s not!Rheumatology (Oxford)20094833234119155279
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAssessment report. Benlysta. International non-proprietary name: belimumab. Procedure No EMEA/H/C/002015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002015/WC500110152.pdfAccessed July 22, 2014
   Google Scholar
• BertiasGIoannidisJPBoletisJEULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including TherapeuticsAnn Rheum Dis20086719520517504841
   PubMed Web of Science ®Google Scholar
• Fischer-BetzRHiepeFKommission Pharmakotherapie der DGRhRevision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosusZ Rheumatol2007667882 German17216418
   PubMed Web of Science ®Google Scholar